ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 463

High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthtitis

Cleandro Albuquerque1, Ana Reis 2, Ana Santos 3, Claiton Brenol 4, Ivanio Pereira 5, Karina Bonfiglioli 6, Manoel Bertolo 7, Maria Guimarães 8, Maria Sauma 9, Paulo Filho 10, Rina Giorgi 11, Sebastião Radominski 12, Licia Mota 1 and Geraldo Castelar 3, 1UnB, Brasília, Brazil, 2UniCeub, Brasília, Brazil, 3UERJ, Rio de Janeiro, Brazil, 4Universidade Federal do Rio Grande do Sul, Porto Alegre, 5UFSC, Florianópolis, Brazil, 6Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, 7University of Campinas, Campinas, Brazil, 8UFMG, Belo Horizonte, Brazil, 9UFPA, Belém, Brazil, 10USP, São Paulo, Brazil, 11Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil, 12Universidade Federal do Paraná, Curitiba, Brazil

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Rheumatoid arthritis (RA), Rheumatoid Factor and outcomes

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 10, 2019

Session Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The rheumatoid factors (RF) have established roles in rheumatoid arthritis (RA) diagnosis, prediction of disease onset and drug response, and in classifying patients as to prognosis. We assessed the influences of RF presence and titration on real-life management outcomes in a large multicenter RA cohort. 

Methods: From August, 2015 to April, 2016, the REAL Study enrolled adult patients diagnosed with RA, according to ARA (1987) or ACR/EULAR (2010) criteria, from eleven Brazilian tertiary healthcare centers. Structured clinical interview and assessment of medical records were performed. DAS28-ESR score, treat to target (T2T) goal attainment (DAS28-ESR < 3.2), disability (HAQ), RF titers, and the presence of erosive disease (EULAR definition) were assessed, as well as several other clinical and demographic variables. A high-titer RF was defined as ≥ 3x the upper limit of normality. Student’s t test, Mann-Whitney U, Kruskal-Wallis test, chi-square, and Fisher’s exact test were used as appropriate.

Results: 1116 patients were included; 89.4% female and 56.8% white. The mean (SD) age was 57.1 (11.5) years; disease duration: 174.7 (115.1) months; schooling years: 8.3 (4.7). Mean DAS28-ESR was 3.6 (1.5); HAQ score 0.943 (0.769). Only 41.3% of patients were within the T2T goal for DAS28. RF was positive in 78.6% of all patients, and in high titers in 56.1%. Erosive disease was found in 54.9%. The median delay from first symptoms to first DMARD was 12 months (IQR=36). RF titers categories (negative, low and high positive) were comparable as to background characteristics: gender, race, age, disease duration, schooling years, and delay from first symptoms to first DMARD (p >0.05 for all comparisons).  The high-titer RF category as compared to the non-high (combined negative or low-titer) RF category showed higher DAS28-ESR scores [3.8(1.5) vs. 3.4(1.5); p< 0.001]; higher HAQ scores [0.999(0.796) vs. 0.870(0.728); p=0.012]; lower attainment of T2T goals [37.2% vs. 46.9%; OR 0.67 (95%CI: 0.51—0.87)]; higher usage of corticosteroids [52.4% vs. 40.2%; OR 1.64 (95%CI: 1.29—2.08)]; higher biological DMARD usage [39.3% vs. 30.9%; OR 1.45 (95%CI: 1.12—1.86)], and higher frequency of extra-articular manifestations [26% vs. 19.6%; OR 1.45 (95%CI: 1.08—1.92)]. Negative and positive low-titer RF categories showed no significant differences between themselves, as to any of the aforementioned outcome variables. Erosive disease was not associated with the RF titer categories (p=0.097).

Conclusion: High-titer RF was associated with worse outcomes in real-life management of RA, with higher disease activity and disability, lower attainment of T2T goals, higher usage of both corticosteroids and biological DMARDs, and higher frequency of extra-articular manifestations. Erosive disease was not associated with RF titer categories in this study, possibly because of the long delay in initiating DMARDs in all RF titer categories, and the overall high frequency of erosions in this population.  Negative and low-titer RF categories seemed to perform similarly, regarding clinical outcomes in real-life management of rheumatoid arthritis. 


Disclosure: C. Albuquerque, None; A. Reis, None; A. Santos, None; C. Brenol, None; I. Pereira, None; K. Bonfiglioli, None; M. Bertolo, None; M. Guimarães, None; M. Sauma, None; P. Filho, None; R. Giorgi, None; S. Radominski, None; L. Mota, None; G. Castelar, None.

To cite this abstract in AMA style:

Albuquerque C, Reis A, Santos A, Brenol C, Pereira I, Bonfiglioli K, Bertolo M, Guimarães M, Sauma M, Filho P, Giorgi R, Radominski S, Mota L, Castelar G. High-titer Rheumatoid Factor Impacts Real-life Management Outcomes of Rheumatoid Arthtitis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/high-titer-rheumatoid-factor-impacts-real-life-management-outcomes-of-rheumatoid-arthtitis/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/high-titer-rheumatoid-factor-impacts-real-life-management-outcomes-of-rheumatoid-arthtitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.